跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BORTEZOMIB - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BORTEZOMIB
Authorized
STANDARD
BORTEZOMIB
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
bbdfce266752b0e9
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
bbdfce266752b0e9
Drug Approval Canada Name
BORTEZOMIB
Product Name
BORTEZOMIB
Status
Marketed
Status Date
2019-03-25
Original Market Date
2019-03-25
Din
02456176
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous , Subcutaneous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01XG01 BORTEZOMIB
Atc Name
l 01 xg 01
Aig Number
0150433001
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)
3.5 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
bbdfce266752b0e9
Type
Standard
Back to Health Canada Approvals